Cancer (solid tumors)
SRK-181 for cancer (solid tumors)
We are investigating SRK-181, a selective inhibitor of latent TGFβ1 activation for the treatment of locally advanced or metastatic solid tumors.
We believe SRK-181 has the potential to make resistant solid tumors vulnerable to immune checkpoint inhibitors such as anti-PD-1/PD-L1 therapies. By targeting the precursor, or latent, form of the TGFβ1 growth factor, SRK-181 could render tumors vulnerable to anti-PD1 therapy and drive tumor regression through combination therapy.
While anti-PD-(L)1 therapies represent a revolutionary treatment option for patients with cancer, this therapeutic approach is only effective in a small subset of patients. Efforts to evaluate checkpoint inhibitors in combination therapy settings to overcome tumor resistance have been met with disappointing clinical results and failures. However, our preclinical studies demonstrate that targeting the precursor, or latent, form of the TGFβ1 growth factor can render tumors vulnerable to anti-PD1 therapy and drive tumor regression through combination therapy. By selectively targeting TGFβ1, we have also observed manageable safety profile.
Clinical Trials
DRAGON
DRAGON is a Phase 1 clinical trial evaluating the safety and efficacy of SRK-181 in patients with locally advanced or metastatic solid tumors that have shown primary resistance to checkpoint inhibitor therapies.
